3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
115
Bevacizumab
72
Radiotherapy
52
Radiation
23
Erlotinib Hydrochloride
13
Lomustine
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Vorinostat
10
Nivolumab
10
Surgical Procedures, Operative
9
Irinotecan
9
Sorafenib
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
7
Immunoglobulin G
7
Everolimus
7
Drug Therapy
7
Disulfides
7
Radiosurgery
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Carmustine
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Sirolimus
5
Cilengitide
5
veliparib
4
veledimex
4
temsirolimus
4
selinexor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Glioblastoma
×
Trabedersen
×
Clear all
NCT00761280
2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3
Terminated
27 enrolled
28 charts